文献速递肿瘤 PET/CT放射性药物与辐射防护

新型纳米抗体68Ga-NODAGA-SNA006用于CD8+ T细胞即时PET显像的初步研究

Pilot study of a novel nanobody 68 Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-07-13

该初步研究设计了一种无六聚组氨酸标签的新型纳米抗体SNA006-GSC,经位点特异性偶联NODAGA-maleimide并标记68Ga,在MC38-CD8+/CD8-荷瘤小鼠和食蟹猴中评估PET显像,并对3例肺癌志愿者行全身PET/CT。结果显示该示踪剂放化纯>98%、比活度>100 GBq/μmol,可在1小时内特异性摄取于CD8+肿瘤病灶,血液清除快(t1/2<20 min),摄取与CD8表达呈初步定量线性关系,所有患者耐受良好。

要点

  • 68Ga-NODAGA-SNA006放化纯>98%、比活度>100 GBq/μmol,1小时内可特异性显像CD8+病灶。
  • 3例志愿者血液清除快(t1/2<20 min),示踪剂摄取与CD8表达呈初步定量线性关系。
  • 所有患者耐受良好,有望用于动态追踪CD8+ T细胞和监测免疫治疗反应。

核心结论

  • 68Ga-NODAGA-SNA006 PET显像可即时定量CD8表达,安全性理想,有望用于动态追踪CD8+ T细胞和监测个体化癌症免疫治疗中的免疫反应。

研究设计与样本

  • 设计无六聚组氨酸标签的新型纳米抗体SNA006-GSC,位点特异性偶联NODAGA-maleimide并用68Ga标记。
  • 在BALB/c MC38-CD8+/CD8-肿瘤模型和食蟹猴中评估68Ga-NODAGA-SNA006的PET显像特征。
  • 3例肺癌志愿者在给予68Ga-NODAGA-SNA006后接受全身PET/CT显像,并研究患者体内的生物分布、药代动力学和剂量测定。
  • 结合免疫组织化学(IHC),在BALB/c MC38-CD8+/CD8-模型和人体中评估该示踪剂监测CD8表达的定量性能。

主要发现

  • 68Ga-NODAGA-SNA006放化纯(RCP)>98%,比活度(SA)>100 GBq/μmol。
  • 68Ga-NODAGA-SNA006在MC38-CD8+异种移植瘤、食蟹猴CD8丰富组织(如脾脏)和患者CD8+肿瘤病灶中1小时内出现特异性摄取。
  • 3例志愿者中观察到血液快速清除(t1/2<20 min)。
  • 68Ga-NODAGA-SNA006摄取与CD8表达之间出现初步定量线性关系,异种移植瘤R2=0.9668、p<0.0001,肺癌患者R2=0.7924、p=0.0013。
  • 所有患者对68Ga-NODAGA-SNA006耐受良好。

关键数值与推荐

  • 68Ga-NODAGA-SNA006放化纯>98%,比活度>100 GBq/μmol。
  • 血液清除半衰期t1/2<20 min(3例志愿者)。
  • 异种移植瘤中示踪剂摄取与CD8表达的定量线性关系R2=0.9668,p<0.0001。
  • 肺癌患者中示踪剂摄取与CD8表达的定量线性关系R2=0.7924,p=0.0013。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Positron emission tomography (PET) with specific diagnostic probes for quantifying CD8+ T cells has emerged as a powerful technique for monitoring the immune response. However, most CD8+ T cell radiotracers are based on antibodies or antibody fragments, which are slowly cleared from circulation. Herein, we aimed to develop and assess 68 Ga-NODAGA-SNA006 for instant PET (iPET) imaging of CD8+ T cells. METHODS: A novel nanobody without a hexahistidine (His6) tag, SNA006-GSC, was designed, site-specifically conjugated with NODAGA-maleimide and radiolabelled with 68 Ga. The PET imaging profiles of 68 Ga-NODAGA-SNA006 were evaluated in BALB/c MC38-CD8+/CD8- tumour models and cynomolgus monkeys. Three volunteers with lung cancer underwent whole-body PET/CT imaging after 68 Ga-NODAGA-SNA006 administration. The biodistribution, pharmacokinetics and dosimetry of patients were also investigated. In addition, combined with immunohistochemistry (IHC), the quantitative performance of the tracer for monitoring CD8 expression was evaluated in BALB/c MC38-CD8+/CD8- and human subjects. RESULTS: 68 Ga-NODAGA-SNA006 was prepared with RCP > 98% and SA > 100 GBq/μmol. 68 Ga-NODAGA-SNA006 exhibited specific uptake in MC38-CD8+ xenografts tumours, CD8-rich tissues (such as the spleen) in monkeys and CD8+ tumour lesions in patients within 1 h. Fast washout from circulation was observed in three volunteers (t1/2 < 20 min). A preliminary quantitative linear relationship (R2 = 0.9668, p < 0.0001 for xenografts and R2 = 0.7924, p = 0.0013 for lung patients) appeared between 68 Ga-NODAGA-SNA006 uptake and CD8 expression. 68 Ga-NODAGA-SNA006 was well tolerated by all patients. CONCLUSION: 68 Ga-NODAGA-SNA006 PET imaging can instantly quantify CD8 expression with an ideal safety profile and is expected to be important for dynamically tracking CD8+ T cells and monitoring immune responses for individualised cancer immunotherapy. TRIAL REGISTRATION: NCT05126927 (19 November 2021, retrospectively registered).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang Y, Wang C, Huang M, et al. Pilot study of a novel nanobody 68 Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells. Eur J Nucl Med Mol Imaging. 2022. PMID: 35829748. doi:10.1007/s00259-022-05903-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。